Daiichi Sankyō Kabushiki-gaisha
GPTKB entity
Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
gptkb:public_company |
| gptkbp:CEO |
gptkb:Sunao_Manabe
|
| gptkbp:country |
gptkb:Japan
|
| gptkbp:focusArea |
oncology
cardiovascular diseases |
| gptkbp:formedByMergerOf |
gptkb:Sankyo_Co.,_Ltd.
gptkb:Daiichi_Pharmaceutical |
| gptkbp:founded |
2005
|
| gptkbp:headquarters_location |
gptkb:Tokyo,_Japan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Daiichi Sankyō Kabushiki-gaisha
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:languageOfName |
Japanese
|
| gptkbp:notableProduct |
gptkb:Enhertu
gptkb:Edoxaban gptkb:Olmesartan |
| gptkbp:numberOfEmployees |
~16,000
|
| gptkbp:parentCompany |
Daiichi Sankyō Group
|
| gptkbp:revenue |
over 1 trillion yen (2023)
|
| gptkbp:romanization |
Daiichi Sankyo Co., Ltd.
|
| gptkbp:servesArea |
worldwide
|
| gptkbp:stockExchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:stockSymbol |
4568
|
| gptkbp:subsidiary |
gptkb:Daiichi_Sankyo,_Inc._(USA)
gptkb:Daiichi_Sankyo_Europe_GmbH |
| gptkbp:website |
https://www.daiichisankyo.com/
|
| gptkbp:bfsParent |
gptkb:Daiichi_Sankyo
|
| gptkbp:bfsLayer |
6
|